Y-27632 Dihydrochloride: Potent ROCK Inhibitor for Cell Research

Executive Summary: Y-27632 dihydrochloride is a well-validated small-molecule inhibitor targeting the catalytic domains of ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM), with over 200-fold selectivity against kinases such as PKC, PKA, MLCK, and PAK (source: product_spec). By disrupting Rho-mediated actin stress fiber formation, Y-27632 modulates cell cycle progression and cytokinesis (source: review). It enhances the viability and expansion of primary and pluripotent stem cells, supporting advanced models for germ cell specification (source: DOI). Animal studies demonstrate its efficacy in suppressing tumor invasion and metastasis, especially via ROCK2 inhibition (source: review). For optimal results, solutions should be prepared fresh, stored below -20°C, and shielded from light (source: product_spec).

Biological Rationale

Rho-associated kinases (ROCK1 and ROCK2) are serine/threonine kinases downstream of Rho GTPases. They orchestrate actin cytoskeletal dynamics, cell adhesion, motility, contractility, and cell cycle progression. Dysregulation of ROCK signaling is implicated in tumorigenesis, fibrotic disease, and abnormal tissue remodeling (source: mechanistic_review). Y-27632 dihydrochloride, supplied by APExBIO (SKU: A3008), was engineered to inhibit ROCK1/2 selectively, providing researchers with a tool to modulate Rho-mediated actin reorganization, cell proliferation, and survival without broad off-target effects (source: product_spec).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively binds the ATP-binding pocket of the ROCK1 and ROCK2 catalytic domains. This prevents substrate phosphorylation, notably of myosin light chain (MLC), and inhibits downstream effectors involved in actin polymerization and stress fiber assembly (source: cytoskeletal_review). The compound's high specificity (IC₅₀ ~140 nM for ROCK1; K_i ~300 nM for ROCK2) allows for robust inhibition at low micromolar concentrations, while sparing kinases such as PKC, PKA, MLCK, and PAK by a margin exceeding 200-fold (source: product_spec). Inhibition of ROCK activity disrupts the formation of actin stress fibers, reduces cell contractility, and alters cell cycle checkpoints, especially the G1/S transition (source: review).

Evidence & Benchmarks

• Y-27632 dihydrochloride exhibits an IC₅₀ of 140 nM for ROCK1 and a K_i of 300 nM for ROCK2, with >200-fold selectivity over PKC and MLCK (source: product_spec).
• In pluripotent stem cell cultures, addition of 10 μM Y-27632 significantly improves human and mouse cell viability and clonal expansion (source: DOI).
• Cellular studies show rapid (<24 h) disassembly of actin stress fibers and focal adhesions following Y-27632 exposure (source: cytoskeletal_review).
• Animal models demonstrate reduced tumor invasion and metastatic spread with ROCK2 inhibition by Y-27632 (source: review).
• Y-27632 is soluble to ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water (source: product_spec).

This article updates and extends the mechanistic focus of the Strategic ROCK Inhibition in Translational Research review by providing quantitative benchmarks and protocol parameters specific to Y-27632 dihydrochloride in stem cell and tumor models.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely adopted in research on cytoskeletal modulation, cancer cell invasion, and stem cell maintenance. It is a standard supplement in protocols for the derivation and expansion of pluripotent stem cells, including naive, primed, and formative states (source: DOI). In cancer research, Y-27632 is used to inhibit tumor cell motility and metastasis by blocking ROCK2 signaling during early tumorigenic transformation (source: review).

For robust cell-based assays, high solubility in aqueous and organic solvents supports precise dosing and reproducible results (source: protocol_review). However, Y-27632 is not suitable for long-term solution storage at room temperature or for therapeutic applications in humans, as all current evidence is preclinical or cell-based (source: workflow_recommendation).

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit upstream Rho GTPases; it is selective for ROCK1/2 catalytic domains (source: product_spec).
• It is ineffective in inducing pluripotency by itself; it supports survival but does not reprogram cell fate (source: DOI).
• Chronic exposure at high concentrations can induce off-target effects in some cell types (source: review).
• It should not be equated with pan-kinase inhibitors, as its selectivity profile is narrow (source: cytoskeletal_review).
• Y-27632 is not a substitute for matrix proteins or growth factors in stem cell culture (source: workflow_recommendation).

For additional context on workflow optimization, see Optimizing Cell Assays with Y-27632 dihydrochloride, which provides troubleshooting and interpretation guidance—this article focuses more on quantitative benchmarks and evidence synthesis.

Workflow Integration & Parameters

Protocol Parameters

• stem cell viability assay | 10 μM | mouse/human PSC cultures | Enhances post-dissociation survival and clonal outgrowth | DOI
• tumor invasion assay | 5–20 μM | in vitro migration/invasion | Inhibits motility and invasion through ROCK2 blockade | review
• solution solubility | ≥111.2 mg/mL (DMSO), ≥52.9 mg/mL (water) | stock preparation | Enables high-concentration stocks for dosing flexibility | product_spec
• storage temperature | <-20°C (solution); 4°C (solid, desiccated) | all applications | Maintains compound integrity and potency | product_spec
• long-term solution storage | not recommended (max 2–4 weeks at -20°C) | all | Prevents degradation and loss of potency | workflow_recommendation

For a mechanistic overview of cytoskeletal impacts, see Y-27632 Dihydrochloride: Selective ROCK Inhibition for Neural and Cancer Research. This article adds quantitative guidance for cell culture and tumor models.

Conclusion & Outlook

Y-27632 dihydrochloride is a cornerstone reagent enabling targeted modulation of the Rho/ROCK pathway in cell biology, stem cell, and cancer research. Its potency, selectivity, and robust solubility profile underpin reliable inhibition of actin stress fiber formation, improvement of stem cell viability, and suppression of tumor invasion in preclinical models (source: DOI). While future translational applications remain under investigation, Y-27632's value as a research tool is well established. Continued use in cell-based and animal models will clarify its scope and limitations, as highlighted by recent literature benchmarks and best practices. For detailed product information and ordering, visit the APExBIO Y-27632 dihydrochloride page.